Status:
UNKNOWN
Transcranial Direct Current Stimulation and Early Alzheimer's Disease (tDCS-AD)
Lead Sponsor:
Benjamin CALVET
Conditions:
Alzheimer Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
TDCS is a rapidly expanding technique, used to treat cognitive difficulties associated with many pathologies (Parkinson's disease, rehabilitation after head trauma, etc.), but which remains of the fie...
Detailed Description
Alzheimer's disease and related syndromes have become a major public health priority issue in France. Pharmacological treatments are ineffective and symptomatic, and only delay the progression of the ...
Eligibility Criteria
Inclusion
- A man or woman with probable Alzheimer's disease diagnosed according to the criteria of the National Institute of Neurological and Communicative Disorders Association (NINCDS-ADRDA)
- Age ≥ 60 years
- Mini Mental State Examination ≥ 18
- Clinical Demential Rating ≤ 1
- Availability of a caregiver for assessments
- Patient care in Day Hospital
- Informed consent of the subject or his legal representative
- General somatic state consistent with study procedures
Exclusion
- Presentation of contraindications to tDCS (presence of intracranial metal implants, intracranial hypertension, comitial risk).
- In case of anticholinesterase treatment: taken for at least 6 months and at a non stable dose for 4 months.
- Taking an antagonist treatment of NMDA receptors (anodic and cathodic) which cancels post-stimulation effects (memantine).
- Other types of dementia or neurological disorder according to Diagnostic and Statistical Manual of Mental Disorders-5 (dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease, Huntington's disease, stroke, major head trauma, cerebral neoplasia, systemic disease ...) , Which can lead to alterations in the functioning of the central nervous system.
- psychiatric disorder according to DSM-5, other than Alzheimer's disease including amnestic disorders, delirium, schizophrenia or schizoaffective disorder, bipolar disorder, major depressive episode in progress, psychosis, panic attacks, post traumatic stress disorder And / or cognitive impairment not otherwise specified.
- Any other disorder for which treatment is given priority over the treatment of Alzheimer's disease or is likely to interfere with the study treatment or impairing adherence.
- Accommodation in an institution (EHPAD, EHPA) or request in progress.
- Participation in other biomedical research during the study that may interfere with the objectives of the study.
- Person who had a recent change (\<1 month) of psychotropic treatment.
- Person with a place of residence more than 80 km away.
- Person without health insurance.
Key Trial Info
Start Date :
June 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 6 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03288363
Start Date
June 6 2017
End Date
December 6 2024
Last Update
October 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Esquirol
Limoges, France, 87025